Browse drugs

…%) had a PSSD > 20 and were referred. Among them, 61.4% were on adalimumab, and 54.5% were on first-line therapy. The median PASI score at…

…re recorded. At the end of follow-up, two patients continued on risankizumab monotherapy, while three maintained the combination therapy.Con…

…arthritis was the most frequent diagnosis (30%).Drugs involved: adalimumab (35%), etanercept (25%), certolizumab (8%), belimumab (6%), ixe…

…ance to 538 patients. The most frequently dispensed drugs were: adalimumab (20.60%) and etanercept (12.40%). The most common prescribing m…

…erval (33.3%) and to restart the drug (25.0%). In patients with ustekinumab, the main interventions were to shorten the dosing interval (55…

…: p=0,0482; Anti-IL12/23 vs Anti-TNF: p=0,0480; Risankizumab vs Ustekinumab: p=0,0116. No significant differences were found between Risank…

…ents received upadacitinib(47.7%), 15 tofacitinib(34.1%), and 8 filgotinib(18.2%). Thirteen patients (29,5%) received concomitant treatmen…

…d of care (initial prednisolone; Arm A) with the anti-TNF drug, adalimumab without glucocorticoids (Arm B).The primary outcome is glucocor…

…er during flares. Three novel TNFAIP3 variants were identified. Colchicine was effective as monotherapy in 40%. TNF-inhibitors showed the …

…ment with seton placement and concomitant anti-TNF (infliximab, adalimumab) allows wound healing in 40%–70% of cases. The currently availa…

…present a case of a woman in her early 30s who was commenced on certolizumab, another TNF-α inhibitor, for the management of her psoriasis, …

…hn’s disease were followed-up after initiation of infliximab or adalimumab. A frailty index (FI) was constructed using variables collected…